c
2
12
18
28
12
12
1a
14
e
12
16
a
a
2
2
a
20
32
1a
2a
19
Faculty
61 16
19
1
49
2
2
1a
32
34
1b
1d
18
38
53
1d
2 29
1d
25
Beverly L. Davidson, Ph.D.
78
53
Professor of Pathology and Laboratory Medicine
7
78
Department: Pathology and Laboratory Medicine
4
1
23
1f
Graduate Group Affiliations
8
a
b
1d
46
Contact information
55
4
3
3
3
2
29
4
b
1f
55
The Children's Hospital of Philadelphia
49 3501 Civic Center Boulevard, 5060 CTRB
Philadelphia, PA 19104
26
49 3501 Civic Center Boulevard, 5060 CTRB
Philadelphia, PA 19104
2e
Office: 267-426-0929
3e Lab: 267-425-2162
18
87
3e Lab: 267-425-2162
18
Email:
davidsonbl@chop.edu
12
davidsonbl@chop.edu
13
Education:
21 9 B.S. 3c (Biology Major/Chemistry Minor; High Distinction) c
35 Nebraska Wesleyan University, 1981.
21 a Ph.D. 21 (Biological Chemistry) c
2f University of Michigan, 1987.
c
3
3
3
3
92
Permanent link21 9 B.S. 3c (Biology Major/Chemistry Minor; High Distinction) c
35 Nebraska Wesleyan University, 1981.
21 a Ph.D. 21 (Biological Chemistry) c
2f University of Michigan, 1987.
c
2 29
21
1e
1d
24
76
23 Neurodegenerative Disease
15 RNA biology
16 Gene therapy
18 Animal models
19 Human treatment
8
209 Our lab is focused on genetic diseases that affect the brain. We study the mechanisms by which mutant gene products contribute to disease, and why certain brain regions are more susceptible. The team employs advanced molecular methods, sequencing and imaging modalities in animal models. The lab is also engaged in the development of next generation therapeutics for inherited disorders, including the engineering of novel gene therapy vector capsids and cargo to approach tissue and cell type specific treatments.
e 29
27
Description of Research Expertise
1a Keywords:23 Neurodegenerative Disease
15 RNA biology
16 Gene therapy
18 Animal models
19 Human treatment
8
209 Our lab is focused on genetic diseases that affect the brain. We study the mechanisms by which mutant gene products contribute to disease, and why certain brain regions are more susceptible. The team employs advanced molecular methods, sequencing and imaging modalities in animal models. The lab is also engaged in the development of next generation therapeutics for inherited disorders, including the engineering of novel gene therapy vector capsids and cargo to approach tissue and cell type specific treatments.
e 29
23
17e Amado DA, Robbins AB, Whiteman KR, Smith AR, Chillonon G, Chen Y, Fuller JA, Patty NA, Izda A, Cheng C, Nelson S, Dichter AI, Mazzoni EO, Monteys AM, Davidson BL: Author Correction: AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 mice. Nat Commun 16(1): 9356, Oct 2025.
12d Carrell ST, Carrell EM, Giovenco R, Davidson BL: Co-Opting MBNL-Dependent Alternative Splicing Cassette Exons to Control Gene Therapy in Myotonic Dystrophy. Ann Neurol Aug 2025 Notes: doi: 10.1002/ana.78024. Epub ahead of print.
169 Amado DA, Robbins AB, Whiteman KR, Smith AR, Chillon G, Chen Y, Fuller JA, Patty NA, Izda A, Cheng C, Nelson S, Dichter AI, Mazzone EO, Montey AM, Davidson BL: AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 mice. Nat Commun 16(1): 5334, June 2025.
16b Amado DA, Robbins AB, Whiteman KR, Smith AR, Chillon G, Chen YH, Fuller JA, Patty NA, Izda A, Cheng C, Nelson S, Dichter AI, Mazzoni EO, Monteys AM, Davidson BL: AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 mice. Nat Commun 16(1): 5334, June 2025.
f3 Matuszek Z, Brown BL, Yrigollen CM, Keiser MS, Davidson BL: Current trends in gene therapy to treat inherited disorders of the brain. Mol Ther 33(5): 1988-2014, May 2025.
158 Leib DE, Chen YH, Tecedor L, Ranum PT, Meiser MS, Lewandowski BC, Carrell EM, Arora S, Huerta-Ocampo I, Lai D, Fluta CM, Cheng C, Liu X, Davidson, BL: Optimized AAV capsids for basal ganglia diseases show robust potency and distribution. Nat Commun 16(1): 4653, May 2025.
188 Tecedor L, Chen YH, Leib DE, Ranum PT, Keiser MS, Lewandowski BC, Carrell EM, Lysenko E, Huerta-Ocampo I, Arora S, Cheng C, Liu X, Davidson, BL: An AAV variant selected through NHP screens robustly transduces the brain and drives secreted protein expression in NHPs and mice. Sci Transl Med 17(798): eadr2531, May 2025.
18b Barbieri EM, Linsenmeier M, Whiteman KR, Cheng Y, Braganza S, Copley KE, Miranda-Castrodad P, Lewis B, Villafane K, Amado DA, Davidson BL, Shorter J: Scouring the human Hsp70 network uncovers diverse chaperone safeguards buffering TDP-43 toxicity. bioRxiv 2025.05.10.653282, May 2025 Notes: doi: 10.1101/2025.05.10.653282.
18c Haley RM, Padilla MS, El-Mayta RD, Joseph RA, Weber JA, Figueroa-Espada CG, Mukalel AJ, Ricciardi AS, Palanki R, Geisler HG, Jester MT, Davidson BL, Mitchell MJ: Lipid nanoparticles for in vivo lung delivery of CRISPR-Cas9 ribonucleoproteins allow gene editing of clinical targets. ACS Nano 19(14): 13790-13804, April 2025.
2c
7
1d
1f
Selected Publications
187 Chamberlain JS, Davidson BL, George LA, Bryne BJ, Barrett D: The future of gene therapy: Safer vectors, sharper focus: High-profile failures demand deep root cause analysis - but the transformative potential of AAV remains within reach if the field is willing to learn and evolve. Mol Ther 33(10): 4694-4695, Oct 2025.17e Amado DA, Robbins AB, Whiteman KR, Smith AR, Chillonon G, Chen Y, Fuller JA, Patty NA, Izda A, Cheng C, Nelson S, Dichter AI, Mazzoni EO, Monteys AM, Davidson BL: Author Correction: AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 mice. Nat Commun 16(1): 9356, Oct 2025.
12d Carrell ST, Carrell EM, Giovenco R, Davidson BL: Co-Opting MBNL-Dependent Alternative Splicing Cassette Exons to Control Gene Therapy in Myotonic Dystrophy. Ann Neurol Aug 2025 Notes: doi: 10.1002/ana.78024. Epub ahead of print.
169 Amado DA, Robbins AB, Whiteman KR, Smith AR, Chillon G, Chen Y, Fuller JA, Patty NA, Izda A, Cheng C, Nelson S, Dichter AI, Mazzone EO, Montey AM, Davidson BL: AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 mice. Nat Commun 16(1): 5334, June 2025.
16b Amado DA, Robbins AB, Whiteman KR, Smith AR, Chillon G, Chen YH, Fuller JA, Patty NA, Izda A, Cheng C, Nelson S, Dichter AI, Mazzoni EO, Monteys AM, Davidson BL: AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 mice. Nat Commun 16(1): 5334, June 2025.
f3 Matuszek Z, Brown BL, Yrigollen CM, Keiser MS, Davidson BL: Current trends in gene therapy to treat inherited disorders of the brain. Mol Ther 33(5): 1988-2014, May 2025.
158 Leib DE, Chen YH, Tecedor L, Ranum PT, Meiser MS, Lewandowski BC, Carrell EM, Arora S, Huerta-Ocampo I, Lai D, Fluta CM, Cheng C, Liu X, Davidson, BL: Optimized AAV capsids for basal ganglia diseases show robust potency and distribution. Nat Commun 16(1): 4653, May 2025.
188 Tecedor L, Chen YH, Leib DE, Ranum PT, Keiser MS, Lewandowski BC, Carrell EM, Lysenko E, Huerta-Ocampo I, Arora S, Cheng C, Liu X, Davidson, BL: An AAV variant selected through NHP screens robustly transduces the brain and drives secreted protein expression in NHPs and mice. Sci Transl Med 17(798): eadr2531, May 2025.
18b Barbieri EM, Linsenmeier M, Whiteman KR, Cheng Y, Braganza S, Copley KE, Miranda-Castrodad P, Lewis B, Villafane K, Amado DA, Davidson BL, Shorter J: Scouring the human Hsp70 network uncovers diverse chaperone safeguards buffering TDP-43 toxicity. bioRxiv 2025.05.10.653282, May 2025 Notes: doi: 10.1101/2025.05.10.653282.
18c Haley RM, Padilla MS, El-Mayta RD, Joseph RA, Weber JA, Figueroa-Espada CG, Mukalel AJ, Ricciardi AS, Palanki R, Geisler HG, Jester MT, Davidson BL, Mitchell MJ: Lipid nanoparticles for in vivo lung delivery of CRISPR-Cas9 ribonucleoproteins allow gene editing of clinical targets. ACS Nano 19(14): 13790-13804, April 2025.
2c
4d
22
22
7
10
a
a
2
2
19
18
10
22
10
11
c
5b © The Trustees of the University of Pennsylvania | Site best viewed a in a supported browser. | Site Design: 57 PMACS Web Team. 3 22
10